On March 8, 2022 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported three presentations at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 8-13, 2022 in New Orleans, Louisiana (Press release, Neoleukin Therapeutics, MAR 8, 2022, View Source [SID1234609798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The upcoming AACR (Free AACR Whitepaper) presentations provide additional preclinical data demonstrating the potential for NL-201 to treat hematologic cancers as well as synergy when NL-201 is combined with radiation therapy," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "These compelling findings suggest that NL-201 could benefit patients broadly across many indications and in combination with a wide variety of standard-of-care agents."

Poster Presentations:

NL-201, a de novo agonist of IL-2 and IL-15 receptors, demonstrates antitumor activity in preclinical B cell lymphoma models

Session Title: Immunomodulatory Agents and Interventions 3
Date and Time: Wednesday, April 13, 2022, 9:00 a.m. to 12:30 p.m CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Poster Board Number: 7
Abstract Number: 4227

NL-201, a de novo engineered IL2/IL15 mimic, synergizes with radiation to generate potent antitumor immunity

Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions 1
Date and Time: Monday Apr 11, 2022, 1:30 p.m. to 5:00 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Poster Board Number: 4
Abstract Number: 2067

A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer

Session Title: Phase I Trials in Progress 2
Date and Time: Wednesday, April 13, 2022, 9:00 a.m. to 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 35
Poster Board Number: 11
Abstract Number: CT250